StudyRareStudyRare
Log in to add personal notes on this page.

A 55-year-old presents with personality changes, disinhibition, and language difficulties. Family history reveals a parent with similar dementia and an aunt who died of ALS.

AD; several genes, each acting by a different mechanism (see Mechanism)

GeneProteinKey Features
GRNProgranulinHaploinsufficiency; variable onset (35-87, mean 65); penetrance about 90% by age 75
MAPTTauEarlier, more predictable onset (mean 49.5, tracks family age of onset); parkinsonism common
C9orf72C9orf72GGGGCC hexanucleotide repeat expansion; can cause FTD and/or ALS
TARDBPTDP-43Can cause FTD and/or ALS; + TDP-43 inclusion bodies
CHMP2BESCRT-III protein CHMP2BDanish founder variant; truncated protein, gain of function

Remember: "Granny's Mind Cannot Think Clearly" (each subtype has its own GeneReviews page)

Disease Progression:

  1. Early (frontal/temporal lobe): Behavioral and personality changes (disinhibition, apathy, poor judgment, loss of empathy) and/or language difficulties. Unlike Alzheimer's, memory is relatively preserved early.

  2. Later (motor symptoms may develop):

    • Parkinsonism (especially MAPT)
    • ALS-like features (especially C9orf72, TARDBP): muscle weakness/wasting, swallowing difficulty, fasciculations

The variant class to look for differs by gene.

  • GRN, haploinsufficiency: progranulin is a secreted protein with trophic and anti-inflammatory activity, and it appears to support lysosomal function. Most pathogenic variants are nonsense, frameshift, or splice-site, and a deletion of the locus gives the same disease, so half the normal amount is the cause.
  • MAPT, altered tau isoforms: tau helps assemble and stabilize microtubules. Splicing of exon 10 sets the balance of three-repeat and four-repeat tau; variants shift that balance or make tau more prone to aggregate. p.Pro301Leu usually presents as behavioral variant FTD, p.Asn279Lys as parkinsonism.
  • C9orf72, repeat expansion: 2 to 24 GGGGCC repeats are normal and 61 to more than 4,000 pathogenic. Proposed hits are RNA foci that trap RNA-binding proteins, dipeptide repeat proteins translated from the repeat, and less C9orf72 protein. Repeat size in blood does not predict onset or severity.
  • TARDBP: TDP-43 regulates RNA processing in the nucleus; in disease it leaves the nucleus and aggregates in the cytoplasm, suggesting both loss and toxic gain of function.
  • CHMP2B, gain of function: C-terminally truncated protein blocks endosome fusion with lysosomes.
  • Second most common early-onset dementia (after Alzheimer's)
  • Onset typically 45-65 years
  • Behavioral changes come FIRST, motor symptoms come LATER (if at all)
  • Clinical diagnosis using consensus criteria for behavioral-variant FTD or primary progressive aphasia, supported by neuropsychological testing
  • MRI shows frontal and temporal atrophy; FDG-PET shows frontotemporal hypometabolism (helps distinguish from Alzheimer's)
  • Molecular testing of GRN, MAPT, and C9orf72 in familial disease or early onset; low plasma progranulin suggests GRN haploinsufficiency
  • C9orf72 repeat expansion testing where ALS/FTD features coexist; cascade testing for at-risk relatives (autosomal dominant, reduced penetrance for GRN)
  • No disease-modifying therapy; care centers on behavioral and environmental strategies plus caregiver support
  • SSRIs for disinhibition, compulsions, and agitation; avoid antipsychotics where possible (extrapyramidal sensitivity, especially with parkinsonism)
  • Cholinesterase inhibitors are generally not helpful and may worsen behavior; speech therapy for language variants
  • Screen for and manage emerging ALS features (swallowing, respiratory); advance care and safety planning

"C9orf72 links ALS and FTD": The same GGGGCC hexanucleotide repeat expansion in C9orf72 can cause ALS, FTD, or both. These are on a spectrum.

FTD vs Alzheimer's: FTD = personality/behavioral changes come FIRST, memory is relatively preserved early. AlzheiMErs = MEmory loss comes first.